On Nov. 3rd, Wall Street rendered a swift and brutal verdict on Kimberly-Clark's (NASDAQ: KMB) transformative acquisition of ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently.

A month after claiming a link between Tylenol use and autism, Health Secretary Robert F. Kennedy Jr. now says there's 'not ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Kyle Kennedy was experiencing pain and swelling in his neck but doctors told him he had swollen glands and to take ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

The news comes as Kenvue maker Tylenol has been embroiled in litigation surrounding the alleged relationship between Tylenol ...